期刊文献+

手术切除治疗中央型肝细胞肝癌临床分析 被引量:6

Clinical analysis of surgical resection for centrally located hepatocellular carcinoma
原文传递
导出
摘要 目的探讨中央型肝细胞肝癌(肝癌)手术切除的安全性、可行性和疗效,总结手术治疗经验。方法本组回顾性研究对象为2007年1月至2011年12月在上海交通大学医学院附属新华医院普外科实施手术切除的35例中央型肝癌患者。患者均签署知情同意书,符合医学伦理学规定。男性31例,女性4例,年龄25~69岁,中位年龄46岁。手术方式:肝癌位于肝Ⅳ、Ⅴ段之间者3例,其中2例行左半肝切除术,1例行肿瘤局部切除术;位于Ⅷ段者11例,其中7例行Ⅷ段切除术,4例行右半肝上段(Ⅶ、Ⅷ段)切除术;位于第一肝门者5例,均行中肝叶(Ⅳ、Ⅴ、Ⅷ段)切除术;位于门静脉右前、右后支夹角者7例,其中4例行右肝下段(Ⅴ、Ⅵ段)切除术,另3例行右半肝切除及门静脉取栓术;位于门静脉左、右支、肝右静脉、肝中静脉及下腔静脉之间者2例,2例均行肿瘤局部切除术,其中1例先行左右半肝劈开后再行肿瘤局部切除术;位于下腔静脉背段者7例,其中2例行右后叶(Ⅵ、Ⅶ段)切除术,2例行Ⅶ、Ⅷ段切除术,3例行Ⅴ、Ⅵ段切除术。观察术中出血量、输血量、手术时间、控制出血方法、术中及术后并发症和死亡发生情况。术后随访,应用寿命表法计算患者生存率。结果 35例患者均顺利完成手术,无发生手术相关性死亡,无发生下腔静脉或肝静脉破裂导致的空气栓塞和大出血等严重并发症。术中出血量100~600(280)ml,5例输红细胞悬液2~4 U。手术时间135~265(178)min。术中控制出血方法:行第一肝门阻断22例,阻断时间15~35(24)min,阻断次数1~2次;行左半肝门阻断2例,阻断时间分别为10、15 min,均为一次性阻断;行右半肝门阻断4例,阻断时间20~38(28)min,均为2次阻断;另3例右半肝切除者,切肝前切断肝动脉右支和阻断门静脉右支;行全肝血流阻断4例,下腔静脉阻断时间10~18(13)min,均为一次性阻断。术后并发症包括胆漏1例、膈下积液4例、右侧胸腔积液6例,处理后均治愈,无发生出血和感染。术后1年和3年生存率分别为87.8%和63.0%。结论手术切除治疗中央型肝癌是有效、安全和可行的。术中应选择合适的手术方式和掌握控制肝脏出血方法。 Objective To evaluate the safety, feasibility and therapeutic outcome of surgical resection for centrally located hepatocellular carcinoma(HCC). Methods A total of 35 cases diagnosed as centrally located HCC were enrolled in this retrospective study, who underwent operations from January 2007 to December 2011 at the Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University. Local ethical committee approval had been received and that the informed consent of all participating subjects was obtained. The patients included 31 males and 4 females with median age of 64 years old (range: 25-69 years old). Among three patients with HCC located in Couinaud segments IV and V ,2 cases received left hemihepatoectomy and 1 case received local resection. Among 11 patients with HCC located in Couinaud segments VIII,7 cases underwent hepatic segmentectomy of Ⅷ and the other 4 cases underwent hepatic segmentectomy of Ⅶ and Ⅷ. Among seven patients with HCC located between the fight anterior and posterior branch of portal vein,4 cases received hepatic segmentectomy of V and VI and 3 cases received right hemihepatoectomy plus embolectomy. Two patients had HCC located between the left and right trunk of portal vein, the middle and right hepatic vein, inferior vena cava (IVC). These two cases received local resection and one of them underwent fight and left liver split following resection. Among seven patients with HCC located in apical segment of IVC,2 cases received hepatic segmentectomy of Ⅵ and Ⅶ,2 cases received hepatic segmentectomy of VII and vm and the other 3 cases received hepatic segmentectomy of V and Ⅵ. The volume of intraoperative blood loss and transfusion, operation time, blood loss control, intraoperative and postoperative complications as well as mortality were observed and recorded. All the patients were followed up and Lift Table method was applied to calculate the survival rate. Results All the 35 HCC patients received successful operations and no operative mortality was observed. No complications were observed such as air embolism and massive haemorrhage caused by IVC or rupture of hepatic vein. The intraoperative blood loss were 100-600 ml with the median volume of 280 ml and 5 cases received 2-4 U blood transfusion. The operating time was 135-265 min with the median time of 178 min. The blood loss control methods included 26 cases undergoing the first hepatic portal control (1-2 times hepatic occlusion with time of 15-35 minutes, median time of 24 minutes), 2 cases undergoing left hepatic portal control (olny one-time hepatic occlusion with time of 10, 15 minutes respectively), 4 cases undergoing the right hepatic portal control (2 times of occlusion with time of 20-38 minutes, median time of 28 minutes). The other 3 cases with right hemihepatoectomy had right branch of hepatic artery cut off and the right branch of portal vein blocked up. Four of the 35 patients received total hepatic vascular exclusion with the inferior vena cava blocking time 10-18 (13) rain for just once. The postoperative complications included 1 ease with bile leakage, 4 eases with subdiaphragmatic effusion and 6 eases with fight pleural effusion. All patients with complications were cured without haemorrhage and infections. The 1- and 3-year survival rates were 87.8% and 63.0% respectively. Conclusions Surgical resection is safe and effective for centrally located HCC. Appropriate techniques and blood loss control should be applied during the operation.
出处 《中华肝脏外科手术学电子杂志》 CAS 2012年第3期16-21,共6页 Chinese Journal of Hepatic Surgery(Electronic Edition)
基金 国家"十二五"科技重大专项(2012ZX10002016-014)
关键词 肝细胞 肝切除术 手术中并发症 手术后并发症 Carcinoma hepatocellula Hepatectomy Intraoperative complications Postoperative complications
  • 相关文献

参考文献5

二级参考文献17

  • 1陈孝平.大肝癌外科治疗的选择[J].肝胆胰脾外科杂志,1997,3(2):117-118. 被引量:10
  • 2Hsien-ChungYu,Jin-ShiungCheng,Kwok-HungLai,Chi-PinLin,Gin-HoLo,Chiun-KuLin,Ping-IHsu,Hoi-HungChan,Ching-ChuLo,Wei-LunTsai,Wen-ChiChen.Factors for early tumor recurrence of single small hepatocellular carcinoma after percutaneous radiofrequency ablation therapy[J].World Journal of Gastroenterology,2005,11(10):1439-1444. 被引量:17
  • 3Yamasaki T,Kurokawa F,Shirahashi H,et al.Percutaneous radiofrequency ablation therapy with combined angiography and computed tomography assistance for patients with hepatocellular carcinoma.Cancer,2001,91:1342-1348.
  • 4Izumi N,Asahina Y,Noguchi O,et al.Risk factors for distant recurrence of hepatocellular carcinoma in the liver after complete coagulation by microwave or radiofrequency ablation.Cancer,2001,91:949-956.
  • 5El-Scrag HB. Hepatocellular carcinoma: an epidemiologic view[J]. J Clin Gastroenterol, 2002,35(5 Suppl 2): S72
  • 6Lok AS, McMahon BJ; Practice Cuidelines Committee, et al.Chronic hepatitis B: update of recommendations [J]. Hepatology, 2004,39(3):857
  • 7Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus [J]. Gastroenterology, 2004,126(1):81.
  • 8Hanazaki K, Kajikawa S, Shimozawa N, et al. Survival and recurrence after hepatic resection of 386 consecutive patients with hepatocellular carcinoma [J]. J Am Coll Surg, 2000,191(4):381
  • 9Roayaie S, Frischer JS, Emre SH, et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters[J]. Ann Surg, 2002,235 (4): 533
  • 10Yoo HY, Patt CH, Geschwind JF, et al. The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time [J]. J Clin Oncol, 2003,21(23):4329

共引文献140

同被引文献51

  • 1王义,陈汉,吴孟超,孙延富,尉公田,林川.中央型巨大肝癌的手术切除及疗效观察[J].中华外科杂志,2004,42(17):1025-1028. 被引量:16
  • 2田建明,王飞,叶华,王振堂,杨继金,刘崎,孙飞,陆建平.肝癌的规则性、变异性供血及其临床意义[J].中华放射学杂志,1994,28(2):93-96. 被引量:55
  • 3韦长元,李挺,杨伟萍,姚波.放射性粒子^(125)Ⅰ对兔大血管放射性损伤的实验研究[J].外科理论与实践,2006,11(1):59-60. 被引量:12
  • 4Shi B, Li CH, Chen YW, et al. Preserving hepatic artery flow during portal triad blood inflow occlusion reduces the outgrowth of hepatocarcinoma in mice after ischemia- reperfusion[J]. Hepatol Res, 2013,5 (2) : 243-246.
  • 5Eisenhauer CA, Therasse P, Bogaerts J, et al. New re- sponse evaluation criteria in solid tumours:Revised RE- CIST guideline(version 1. 1) [J]. Cur J Cancer, 2009,45 (2) : 228-247.
  • 6Dillner J,Meyer F, Lippert H, et al. Organ invasive carci noma of the pararenal gland involving the inferior vena ca va:suceessful curative and interdisciplinary surgical man agement[J]. Dtsch Med Wochenschr, 2013,138 ( 6 ) : 260- 265.
  • 7Yang Y, Lai EC,Fu SY, et al. A prospective randomized controlled trial to compare two methods of selective he- patic vascular exclusion in partial hepatectomy[J]. Eur J Surg Oncol,2013,39(2) :125-130.
  • 8Bellemann N, Stampfl U, Sommer CM, et al. Portal vein embolization using a histoacryl/lipiodol mixture before right liver resection[J]. Dig Surg,2012,29(3) :236-242.
  • 9Kim SK, Nasu A, Komori J ,et al. A model of liver carcinogenesis originating from hepatic progenitor cells with accumulation of genetic alterations. Int J Cancer, 2014, 134 ; 1067 -1076.
  • 10Zhang Y, Li Y, Lin C,et al. Aberrant upregulafion of 14-3 3a and EZH2 expression serves as an inferior prognostic biomarker for hepatocellular carcinoma. PLoS One. 2014,9 : el 07251.

引证文献6

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部